EPANOVA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Epanova, and when can generic versions of Epanova launch?
Epanova is a drug marketed by Astrazeneca and is included in one NDA. There are seven patents protecting this drug.
This drug has eighty-four patent family members in forty countries.
The generic ingredient in EPANOVA is omega-3-carboxylic acids. There is one drug master file entry for this compound. Additional details are available on the omega-3-carboxylic acids profile page.
DrugPatentWatch® Generic Entry Outlook for Epanova
Epanova was eligible for patent challenges on May 5, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 20, 2026. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EPANOVA?
- What are the global sales for EPANOVA?
- What is Average Wholesale Price for EPANOVA?
Summary for EPANOVA
| International Patents: | 84 |
| US Patents: | 7 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 16 |
| Patent Applications: | 129 |
| DailyMed Link: | EPANOVA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for EPANOVA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for EPANOVA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| IQVIA RDS Inc. | Phase 3 |
| The Cleveland Clinic | Phase 3 |
| Cleveland Clinic Coordinating Center for Clinical Research (C5R) | Phase 3 |
US Patents and Regulatory Information for EPANOVA
EPANOVA is protected by seven US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of EPANOVA is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting EPANOVA
DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA (500 MG/DL) IN ADULT PATIENTS AS AN ADJUNCT TO DIET
Type A gelatin capsule containing PUFA in free acid form
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Type a gelatin capsule containing PUFA in free acid form
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HYPERTRIGLYCERIDEMIA
Type A gelatin capsule containing PUFA in free acid form
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HYPERTRIGLYCERIDEMIA
DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HYPERTRIGLYCERIDEMIA
DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Type A gelatin capsule containing PUFA in free acid form
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HYPERTRIGLYCERIDEMIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Astrazeneca | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Astrazeneca | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Astrazeneca | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Astrazeneca | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Astrazeneca | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Astrazeneca | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EPANOVA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Astrazeneca | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | ⤷ Sign Up | ⤷ Sign Up |
| Astrazeneca | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for EPANOVA
See the table below for patents covering EPANOVA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Norway | 320780 | ⤷ Sign Up | |
| European Patent Office | 3289750 | RÉCUPÉRATION DE CLÉ PRIVÉE AUTONOME (AUTONOMOUS PRIVATE KEY RECOVERY) | ⤷ Sign Up |
| Colombia | 7061070 | Composiciones enriquecidas con dpa de ácidos grasos omega 3 poliinsaturados en forma de ácido libre | ⤷ Sign Up |
| Peru | 20142459 | COMPOSICIONES ENRIQUECIDAS CON DPA DE ACIDOS GRASOS OMEGA 3 POLIINSATURADOS EN FORMA DE ACIDO LIBRE | ⤷ Sign Up |
| Norway | 341821 | ⤷ Sign Up | |
| South Korea | 20140135695 | DPA-ENRICHED COMPOSITIONS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS IN FREE ACID FORM | ⤷ Sign Up |
| European Patent Office | 0825858 | GELULES POUR DELIVRANCE PROGRESSIVE EN FONCTION DU TEMPS CONTENANT D'ACIDES OMEGA-3 POLYINSATURES POUR LE TRAITEMENT DES MALADIES A'LINFLAMMATION INTESTINALE (TIME-DEPENDANT RELEASE CAPSULES CONTAINING OMEGA-3 POLYUNSATURATED ACIDS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
